Immunic (NASDAQ:IMUX) is scheduled to announce its earnings results before the market opens on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.62) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.79) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.17. On average, analysts expect Immunic to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
NASDAQ:IMUX opened at $17.20 on Friday. Immunic has a twelve month low of $4.19 and a twelve month high of $17.81. The company has a 50-day moving average of $13.60 and a 200-day moving average of $9.83. The firm has a market cap of $257.45 million, a price-to-earnings ratio of -4.66 and a beta of 3.17.
Several equities analysts have recently weighed in on IMUX shares. Wedbush restated a “buy” rating and set a $58.00 price objective on shares of Immunic in a research report on Monday, July 27th. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Immunic in a research report on Tuesday, June 16th. BidaskClub upgraded shares of Immunic from a “hold” rating to a “buy” rating in a research report on Wednesday, July 22nd. Zacks Investment Research lowered shares of Immunic from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. Finally, BMO Capital Markets began coverage on shares of Immunic in a report on Monday, July 20th. They issued an “outperform” rating and a $40.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Immunic currently has a consensus rating of “Buy” and an average target price of $39.83.
In other Immunic news, COO Manfred Groeppel sold 5,650 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $14.58, for a total value of $82,377.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Vitt sold 6,300 shares of the firm’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $14.68, for a total transaction of $92,484.00. The disclosure for this sale can be found here. Company insiders own 12.07% of the company’s stock.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Featured Article: How does quantitative easing work?
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.